Blueprint Medicines Co. (NASDAQ:BPMC) Shares Purchased by E Fund Management Co. Ltd.

E Fund Management Co. Ltd. boosted its holdings in Blueprint Medicines Co. (NASDAQ:BPMC) by 22.9% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,768 shares of the biotechnology company’s stock after acquiring an additional 1,073 shares during the quarter. E Fund Management Co. Ltd.’s holdings in Blueprint Medicines were worth $622,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Principal Financial Group Inc. increased its position in Blueprint Medicines by 331.9% in the 1st quarter. Principal Financial Group Inc. now owns 62,670 shares of the biotechnology company’s stock valued at $5,945,000 after acquiring an additional 48,160 shares during the period. Susquehanna Fundamental Investments LLC bought a new position in Blueprint Medicines during the 1st quarter valued at $474,000. Vanguard Group Inc. boosted its stake in Blueprint Medicines by 2.5% during the 4th quarter. Vanguard Group Inc. now owns 6,114,970 shares of the biotechnology company’s stock valued at $564,045,000 after purchasing an additional 147,827 shares in the last quarter. Comerica Bank boosted its stake in Blueprint Medicines by 2,582.9% during the 1st quarter. Comerica Bank now owns 10,839 shares of the biotechnology company’s stock valued at $1,028,000 after purchasing an additional 10,435 shares in the last quarter. Finally, Axiom Investors LLC DE bought a new position in Blueprint Medicines during the 4th quarter valued at $2,212,000.

Blueprint Medicines Stock Up 3.3 %

Shares of Blueprint Medicines stock opened at $89.33 on Thursday. The firm has a market cap of $5.59 billion, a price-to-earnings ratio of -18.57 and a beta of 0.58. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.71 and a quick ratio of 3.65. Blueprint Medicines Co. has a 52-week low of $43.89 and a 52-week high of $121.90. The stock has a 50-day simple moving average of $99.35 and a 200-day simple moving average of $99.08.

Blueprint Medicines (NASDAQ:BPMC) last announced its quarterly earnings results on Thursday, August 1st. The biotechnology company reported ($0.80) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.29) by $0.49. The business had revenue of $138.20 million during the quarter, compared to analyst estimates of $104.02 million. Blueprint Medicines had a negative return on equity of 157.30% and a negative net margin of 56.64%. The firm’s revenue was up 139.9% on a year-over-year basis. During the same period in the previous year, the company earned ($2.19) EPS. On average, equities research analysts expect that Blueprint Medicines Co. will post -3.99 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

BPMC has been the subject of a number of research reports. Baird R W raised Blueprint Medicines to a “strong-buy” rating in a research note on Friday, August 2nd. Guggenheim increased their price target on Blueprint Medicines from $130.00 to $138.00 and gave the company a “buy” rating in a research note on Friday, August 2nd. Robert W. Baird increased their price target on Blueprint Medicines from $112.00 to $127.00 and gave the company an “outperform” rating in a research note on Friday, August 2nd. Barclays increased their price target on Blueprint Medicines from $75.00 to $105.00 and gave the company an “equal weight” rating in a research note on Monday, July 29th. Finally, Needham & Company LLC reissued a “buy” rating and set a $130.00 price objective on shares of Blueprint Medicines in a research note on Thursday, August 1st. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $120.00.

Insider Buying and Selling

In related news, insider Philina Lee sold 41,913 shares of the business’s stock in a transaction that occurred on Monday, August 5th. The stock was sold at an average price of $93.19, for a total value of $3,905,872.47. Following the completion of the sale, the insider now directly owns 34,729 shares in the company, valued at approximately $3,236,395.51. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Blueprint Medicines news, insider Debra Durso-Bumpus sold 333 shares of Blueprint Medicines stock in a transaction that occurred on Friday, June 28th. The stock was sold at an average price of $111.15, for a total value of $37,012.95. Following the transaction, the insider now directly owns 43,763 shares of the company’s stock, valued at approximately $4,864,257.45. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Philina Lee sold 41,913 shares of Blueprint Medicines stock in a transaction that occurred on Monday, August 5th. The stock was sold at an average price of $93.19, for a total value of $3,905,872.47. Following the completion of the transaction, the insider now directly owns 34,729 shares in the company, valued at $3,236,395.51. The disclosure for this sale can be found here. In the last ninety days, insiders sold 128,947 shares of company stock worth $13,065,852. 4.21% of the stock is currently owned by insiders.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.